EDXC
Endexx Corporation0.0016
+0.0001+8.11%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
914.96KP/E (TTM)
0.16Basic EPS (TTM)
0.01Dividend Yield
0%Recent Filings
8-K
Leadership shakeup at Endexx
Endexx Corporation's Chairman and sole officer Todd Davis resigned from executive roles on June 27, 2024, with the board accepting on July 2; he stays on the board and leads subsidiary CBD Unlimited. The board handled CEO and CFO duties until July 11, appointing Brad Listermann of Strategic Innovations First as interim executive. This shift aims to stabilize leadership amid operational needs. Transition risks linger until permanent hires.
8-K
Auditor dismissal signals concerns
Endexx Corporation dismissed its independent auditor, Turner, Stone & Company, L.L.P., on February 9, 2024, with board approval, triggering this 8-K filing under Item 4.01. The prior audits for fiscal years ended September 30, 2022, and 2021, raised substantial doubt about the company's going concern status but contained no other qualifications or disagreements on accounting matters. No new auditor has been appointed yet. This shift underscores ongoing viability concerns.
10-K
FY2023 results
Endexx Corporation posted FY2023 revenue of $3.9 million, up 83% year-over-year from $2.1 million, fueled by stronger sales channels and marketing for its hemp-derived and plant-based vape products, yet gross profit flipped to a $766K loss from $1.2 million due to a $1.3 million inventory impairment spike and higher costs. Operating expenses dropped 23% to $3.9 million, trimming payroll and professional fees, but other expenses ballooned to $3.7 million from derivative fair-value swings and interest, yielding a net loss of $7.4 million versus $5.1 million last year. Q4 momentum showed revenue acceleration amid recovering markets, though margins compressed sequentially from Q3 on elevated impairments. Liquidity strained with $8K cash and $17.3 million stockholders' deficit, offset by $908K in financing inflows; no dividends or buybacks occurred. No annual guidance disclosed. Evolving FDA regulations on hemp-derived products pose risks to quarterly sales momentum.
8-K
Board appointment ties to services
Endexx Corporation appointed Claude Zdanow to its board on November 1, 2023, as the second director selected by holders of Series H Convertible Preferred Stock, effective October 25. Zdanow, CEO of Integrum Group since March 2023, brings experience from prior CEO roles at Stadiumred and founding ventures. Integrum provides ongoing consulting to Endexx at $25,000 monthly—transitioning to a long-term deal—and management services to subsidiary Hyla at $10,000 monthly, plus prior marketing at $15,000. This ties board oversight to key service providers.
8-K
Endexx uploads company overview
Endexx Corporation filed an 8-K on September 29, 2023, disclosing under Regulation FD the upload of a Company Overview to its website, furnished as Exhibit 99.1. This presentation details the firm's operations and strategy but carries no legal filing status. Investors get a fresh look at Endexx's direction. No financial impacts or forward guidance disclosed.
IPO
Website
Sector
Industry
BUDZ
WEED, Inc.
0.06+0.01
CBDL
CBD Life Sciences Inc.
0.00+0.00
CRLBF
Cresco Labs Inc.
1.75+0.45
CWBHF
Charlotte's Web Holdings Inc.
0.15+0.00
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
NTRR
Neutra Corp.
0.00+0.00
NXEN
Nexien BioPharma, Inc.
0.00+0.00
NXGB
NxGen Brands Inc.
0.00-0.00
VEXTF
Vext Science Inc.
0.22+0.01
YCBD
cbdMD, Inc.
1.43+0.23